{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:22:52Z","timestamp":1787862172417,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:57:42Z","timestamp":1782284262000},"page":"e1123-e1132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Influence of Racial, Socioeconomic, and Geographic Disparities in the Survival of Patients With Plasmablastic Lymphoma: A Population-Based Analysis From the Surveillance, Epidemiology, and End Results (SEER) Database (2000-2022)"],"prefix":"10.1016","volume":"26","author":[{"given":"Shahzaib","family":"Maqbool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ebad UR","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6296-874X","authenticated-orcid":false,"given":"Muhammad","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Imam","family":"Naufil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouzma","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arham","family":"Ihtesham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8157-1037","authenticated-orcid":false,"given":"Muhammad","family":"Ibrahim Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-4264","authenticated-orcid":false,"given":"Muhammad","family":"Osama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-9060","authenticated-orcid":false,"given":"Abat","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose David","family":"Sandoval-Sus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H. Silva","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9210-2191","authenticated-orcid":false,"given":"Amir","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2026.06.012_bib0001","article-title":"Plasmablastic lymphoma. A state-of-the-art review (1): part 1- epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations","volume":"16","author":"Bibas","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2026.06.012_bib0002","unstructured":"Di Ciaccio P. Survival outcomes for plasmablastic Lymphoma: an international, multicentre study by the Australasian lymphoma alliance. 2020 [Accessed: January 9, 2026]. Available at: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper134972.html"},{"issue":"1","key":"10.1016\/j.clml.2026.06.012_bib0003","article-title":"Plasmablastic lymphoma: a systematic review","volume":"11","author":"Castillo","year":"2011","journal-title":"Sci World J"},{"key":"10.1016\/j.clml.2026.06.012_bib0004","doi-asserted-by":"crossref","unstructured":"Latiolais H. A National Cancer database analysis of demographics, treatment patterns and survival trends of patients with plasmablastic lymphoma in US: does ethnicity predict enhanced outcomes? 2023 [Accessed: January 10, 2026]. Available at: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper187774.html","DOI":"10.1182\/blood-2023-187774"},{"issue":"4","key":"10.1016\/j.clml.2026.06.012_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2023.12.014","article-title":"Epidemiologic characteristics, treatment patterns, and survival analysis of plasmablastic lymphoma in the United States: a SEER and NCDB analysis","volume":"24","author":"Hansen","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2026.06.012_bib0006","article-title":"Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation","volume":"1","author":"Becnel","year":"2017","journal-title":"Ann Lymph"},{"issue":"1","key":"10.1016\/j.clml.2026.06.012_bib0007","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/hematology.2025000750","article-title":"When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?","volume":"2025","author":"Castillo","year":"2025","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.clml.2026.06.012_bib0008","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ajh.27376","article-title":"Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Gamero","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2026.06.012_bib0009","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ajh.25955","article-title":"Survival analysis in treated plasmablastic lymphoma patients: a population-based study","volume":"95","author":"Florindez","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2026.06.012_bib0010","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","article-title":"Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuk Lymph"},{"issue":"15","key":"10.1016\/j.clml.2026.06.012_bib0011","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.06.012_bib0012","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.06.012_bib0013","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.clml.2026.06.012_bib0014","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and Rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2026.06.012_bib0015","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","article-title":"Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-hodgkin lymphoma","volume":"118","author":"Barta","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2026.06.012_bib0016","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related burkitt lymphoma\/leukemia","volume":"94","author":"Cortes","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.06.012_bib0017","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2024.015","article-title":"The plasmablastic lymphoma. a state-of-the-art review: part 2-focus on therapy","volume":"16","author":"Bibas","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"8","key":"10.1016\/j.clml.2026.06.012_bib0018","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000000623","article-title":"Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy","volume":"29","author":"Alwan","year":"2015","journal-title":"AIDS"},{"issue":"34","key":"10.1016\/j.clml.2026.06.012_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.30.0038","article-title":"Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone","volume":"28","author":"Bibas","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.06.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2023.05.014","article-title":"Plasmablastic lymphoma: past, present, and future","volume":"23","author":"Kaur","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2026.06.012_bib0021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428194.2014.911867","article-title":"Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center\u2019s experience","volume":"56","author":"Cattaneo","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.clml.2026.06.012_bib0022","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2026.06.012_bib0023","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.06.012_bib0024","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1007\/s00277-024-06075-2","article-title":"Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis","volume":"103","author":"Aqeel","year":"2024","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.clml.2026.06.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.03.006","article-title":"Racial and socioeconomic disparities in mantle cell lymphoma","volume":"19","author":"Shah","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.06.012_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e19546","article-title":"Epidemiological characteristics and cause-specific survival analysis of plasmablastic lymphoma (PBL) using the SEER database","volume":"40","author":"Gor","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.06.012_bib0027","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1055-9965.EPI-21-0103","article-title":"Impact of race, ethnicity, and socioeconomic status over time on the long-term survival of adolescent and young adult Hodgkin Lymphoma survivors","volume":"30","author":"Berkman","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"7","key":"10.1016\/j.clml.2026.06.012_bib0028","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1080\/10428194.2018.1546855","article-title":"Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study","volume":"60","author":"Ritter","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2026.06.012_bib0029","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1080\/10428194.2017.1416365","article-title":"Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis","volume":"59","author":"Dittus","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2026.06.012_bib0030","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/bloodadvances.2024012981","article-title":"New strategies for enhancing enrollment of underrepresented minorities in lymphoma clinical trials","volume":"9","author":"Nze","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2026.06.012_bib0031","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jha2.797","article-title":"Disparities in care and outcomes for adolescent and young adult lymphoma patients","volume":"4","author":"Rosenthal","year":"2023","journal-title":"eJHaem"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:48:49Z","timestamp":1787860129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2152265026001990"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Influence of Racial, Socioeconomic, and Geographic Disparities in the Survival of Patients With Plasmablastic Lymphoma: A Population-Based Analysis From the Surveillance, Epidemiology, and End Results (SEER) Database (2000-2022)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}